[go: up one dir, main page]

EP4601667A1 - Polypeptides associés au facteur de différenciation tissulaire (tdfrp) pour le traitement d'une lésion myocardique - Google Patents

Polypeptides associés au facteur de différenciation tissulaire (tdfrp) pour le traitement d'une lésion myocardique

Info

Publication number
EP4601667A1
EP4601667A1 EP23801981.4A EP23801981A EP4601667A1 EP 4601667 A1 EP4601667 A1 EP 4601667A1 EP 23801981 A EP23801981 A EP 23801981A EP 4601667 A1 EP4601667 A1 EP 4601667A1
Authority
EP
European Patent Office
Prior art keywords
seq
tdfrp
myocardial
injury
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23801981.4A
Other languages
German (de)
English (en)
Inventor
William Dean CARLSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapeutics By Design LLC
Original Assignee
Therapeutics By Design LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutics By Design LLC filed Critical Therapeutics By Design LLC
Publication of EP4601667A1 publication Critical patent/EP4601667A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • cardiomyopathy can develop in people of all ages, races, and ethnicities, and often medical conditions or lifestyle habits can raise the risk of cardiomyopathy. Some types of cardiomyopathy are more common in certain age groups; arrhythmogenic cardiomyopathy is more common in teens and young adults; dilated cardiomyopathy is more common in adults between 20 and 60 years old; hypertrophic cardiomyopathy is more common in people in their 30s; takotsubo cardiomyopathy is more common in women after menopause.
  • Some of the conditions that lead to cardiomyopathy include valvular heart disease, myocardial ischemia, pulmonary diseases, obstructive sleep apnea, inflammation (due to e.g., viral, bacterial, or fungal infection, or autoimmune disease), chemotherapy or radiation treatment for cancer, long term alcohol and drug abuse, heavy metal poisoning, nutritional issues, arrhythmias, constrictive pericarditis, diabetes, hemochromatosis, and complications of late-stage pregnancy.
  • cardiomyopathy Other medical conditions that may lead to cardiomyopathy include Duchenne muscular dystrophy, sarcoidosis or amyloidosis, heart inflammation from endocarditis, myocarditis, or pericarditis, infections, such as viral hepatitis and HIV, obesity, diabetes, or other problems with the metabolic system.
  • Myocardial infarction is a common presentation of coronary artery disease.
  • the World Health Organization estimated in 2004, that 12.2% of worldwide deaths were from ischemic heart disease; with it being the leading cause of death in high- or middle -income countries and second only to lower respiratory infections in lower-income countries.
  • STEMIs occur about twice as often in men as women.
  • IHD is becoming a more common cause of death in the developing world.
  • IHD had become the leading cause of death by 2004, accounting for 1.46 million deaths (14% of total deaths) and deaths due to IHD were expected to double during 1985- 2015.
  • DALYs disability adjusted life years
  • Cardiomyopathy is often characterized by a decrease in the pumping function of the heart.
  • Cardiomyopathy can be caused by a number of conditions including, including but not limited to, valvular abnormalities, hypertension, collagen vascular disease, myocardial ischemia, myocardial infarction, toxins, anticancer therapies, congenital abnormalities, arrhythmias, diabetes and other types of injury.
  • the underlying pathophysiology of cardiomyopathy is characterized by cardiomyocyte apoptosis, inflammation, and fibrosis (scarring). Loss of cardiac function results in increased stress on the heart and thus a worsening of the cardiomyopathic condition resulting in a spiral into congestive heart failure and death.
  • Cardiac injury can be the result of myriad insults, but is mediated through a common pathophysiology including a apoptosis, inflammation, fibrosis, that leads to a syndrome called congestive heart failure or cardiomyopathy.
  • tissue differentiation factor related polypeptides can be used to block and reverse the intracellular pathways in cardiomyocytes that lead to inflammation and apoptosis, thereby preventing necrosis and fibrosis.
  • TDFRPs tissue differentiation factor related polypeptides
  • the present disclosure describes results showing that TDFRPs prevented apoptosis and inflammation in rat cardiomyocytes, and amelioratedthe effects of myocardial ischemia resulting from ischemia/reperfusion injury in vivo. Because the TDFRPs target intracellular pathways that lead to inflammation and apoptosis, the methods described herein are advantageously used to treat or prevent any condition that is associated with myocardial injury
  • the disclosure features a method for treating myocardial injury, or a condition associated with myocardial injury, in a mammal, wherein the method comprises administering at least one tissue differentiation factor related polypeptide (TDFRP) to the mammal, and wherein the administering is in an amount effective to treat myocardial injury in said mammal.
  • TDFRP tissue differentiation factor related polypeptide
  • the disclosure features a method for preventing myocardial injury, or a condition associated with myocardial injury, in a mammal, wherein the method comprises administering at least one tissue differentiation factor related polypeptide (TDFRP) to the mammal, and wherein the administering is in an amount effective to prevent myocardial injury in said mammal.
  • TDFRP tissue differentiation factor related polypeptide
  • the TDFRP is selected from an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the TDFRP is selected from an amino acid sequence at least 91%, 92%, 93%, 94% ,95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the TDFRP comprises SEQ ID NO: 1.
  • the TDFRP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.
  • the TDFRP consists of SEQ ID NO: 1.
  • the mammal is a human.
  • the myocardial injury results from or is associated with an ischemia/reperfusion injury.
  • the ischemia/reperfusion injury results from myocardial infarction, severe trauma, renal insufficiency, pulmonary insufficiency, arterial stenosis, open heart surgery, or doxorubicin chemotherapy.
  • the myocardial injury results from or is associated with a surgical procedure; exposure to a cardiotoxic compound; hypertension; ischemic heart disease; dilated cardiac injury; myocarditis; thyroid disease; viral infection; gingivitis; drug abuse; alcohol abuse; periocarditis; atherosclerosis; vascular disease; hypertrophic cardiomyopathy; acute myocardial infarction; left ventricular systolic dysfunction; coronary bypass surgery; starvation; an eating disorder; or a genetic defect.
  • the cardiotoxic compound is an anthracycline, alcohol, or cocaine.
  • the anthracyline is doxorubicin, or daunomycin.
  • the TDFRP is administered prior to the diagnosis of the myocardial injury, or the condition associated with myocardial injury in the mammal. According to some embodiments of the aspects and embodiments herein, the TDFRP is administered after the diagnosis of the myocardial injury, or the condition associated with myocardial injury in the mammal. According to some embodiments of the aspects and embodiments herein, the mammal is at risk for myocardial injury.
  • the mammal is an individual that smokes, is obese, has been or will be exposed to a cardiotoxic compound, has or had high blood pressure, has or had ischemic heart disease, has or had a myocardial infarct, has a genetic defect that increases the risk of heart failure, has a family history of heart failure, has or had myocardial hypertrophy, has or had hypertrophic cardiomyopathy, has or had left ventricular systolic dysfunction, had coronary bypass surgery, has or had vascular disease, has or had atherosclerosis, has or had alcoholism, has or had pericarditis, has or had a viral infection, has or had gingivitis, has or had an eating disorder, has or had myocarditis, has or had a thyroid disease, or is a cocaine addict.
  • the mammal has or had a cancer.
  • administration of the TDFRP inhibits cardiomyocyte apoptosis.
  • administration of the TDFRP inhibits pericarditis inflammation levels.
  • the TDFRP is administered by a parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, oral, or topical route.
  • the method further comprises administration of an additional agent selected from the group consisting of: anti-neoplastic agents, antibiotics, vaccines, immunosuppressive agents, anti-hypertensive agents and mediators of the hedgehog signaling pathway.
  • an additional agent selected from the group consisting of: anti-neoplastic agents, antibiotics, vaccines, immunosuppressive agents, anti-hypertensive agents and mediators of the hedgehog signaling pathway.
  • FIG. 1 is a graph that shows anti-apopototic activity of THR-123 (SEQ ID NO: 1).
  • Phosphorylated Akt is a marker of apoptosis. Ischemic injury leads to apoptosis. As shown in FIG.l, cell starvation via serum withdrawal led to ischemia and the reduction of phosphorylated AKT in rat cardiomyocytes. Addition of PBS had no effect, whereas addition of THR-123 (SEQ ID NO:1) at 100 pM for 60 h reversed the effects of ischemia on AKT phosphorylation.
  • FIG. 2 is a graph that shows THR-123 (SEQ ID NO: 1) blocked adriamycin(doxorubicin) suppression of pAKT in human cardiomyocytes, thus demonstrating THR-123 anti-apoptotic activity.
  • THR-123 SEQ ID NO: 1
  • doxorubicin adriamycin(doxorubicin) suppression of pAKT in human cardiomyocytes
  • FIG. 2 is a graph that shows THR-123 (SEQ ID NO: 1) blocked adriamycin(doxorubicin) suppression of pAKT in human cardiomyocytes, thus demonstrating THR-123 anti-apoptotic activity.
  • the addition of 333 nM doxorubicin to serum starved cardiomyocytes further reduces phosphorylation of AKT.
  • Addition of SEQ ID No. 1 at 100 pM and at 500 pM reversed the inhibition of AKT phosphorylation in a dose dependent manner.
  • FIG. 3 is a graph that shows THR-123 (SEQ ID NO: 1) and BMP-7 bloced adriamycin (doxorubicin) induction of caspase-3 in human cardiomyocytes, thus demonstrating THR-123 anti- apoptotic activity.
  • addition of 333 pM doxorubicin to cardiomyocytes stimulated caspase-3 activity.
  • Addition of 143 nM BMP-7 or 100 pM or 500 pM THR-123 (SEQ ID NO: 1) completely reversed the apoptotic effects of doxorubicin.
  • FIG. 4 is a graph that shows THR-123 (SEQ ID NO: 1) blocked LPS induction of caspase-3 release in human cardiomyocytes, thus demonstrating THR-123 anti-apoptotic activity.
  • LPS lipopolysaccharide;an endotoxin
  • FIG. 5 is a graph that shows BMP-7 and THR-123 (SEQ ID NO: 1) blocked LPS induction of IL-6 in human cardiomyocytes, thus demonstrating anti-inflammatory activity
  • FIG. 5 exposure of cardiomyocytes to 100 ng/ml LPS resulted in a significant release of inflammatory cytokine IL-6.
  • BMP-7 143 nM
  • FIG. 6 shows a schematic of the time course of the Left Anterior Descending Artery (LAD) model.
  • FIG. 7 shows a schematic of the histomorphometric analysis of the effects of LAD ligation.
  • the area of the necrotic area and the area of the whole area at risk are measured.
  • the areas are summed over all slices to obtain an estimate of the necrotic volume (NV) and the volume at risk (VR).
  • the ratio of NV/VR is a measure of the myocardial injury resulting from the period of ischemia and subsequent reperfusion injury.
  • FIG. 8 is a graph showing the results of the histomorphometric analysis. As shown in FIG.8, there was an 84% reduction in myocardial injury with THR-123 (SEQ ID NO: 1).
  • FIG. 9 is a graph that shows the effect of treatment on pericarditis on inflammation level.
  • tissue differentiation factor related polypeptides TDFRPs
  • analogs, homologs or variants thereof can be used to treat or prevent conditions associated with cardiomyopathy, particularly conditions where cardiomyocytes are stressed or injured leading to inflammation, fibrosis, apoptosis, and/or necrosis.
  • the term “about,” when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ⁇ 20% or ⁇ 10%, more preferably ⁇ 5%, even more preferably ⁇ 1%, and still more preferably ⁇ 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
  • any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.
  • administering refers to introducing a composition or agent into a subject and includes concurrent and sequential introduction of a composition or agent.
  • administering can refer, e.g., to therapeutic, pharmacokinetic, diagnostic, research, placebo, and experimental methods.
  • administering also encompasses in vitro and ex vivo treatments.
  • Administration includes self-administration and the administration by another. Administration can be carried out by any suitable route.
  • a suitable route of administration allows the composition or the agent to perform its intended function. For example, if a suitable route is intravenous, the composition is administered by introducing the composition or agent into a vein of the subject.
  • analog is meant to refer to a composition that differs from the compound of the present disclosure but retains essential properties thereof.
  • a non-limiting example of this is a polypeptide or peptide or peptide fragment that includes non-natural amino acids, peptidomimetics, unusual amino acids, amide bond isosteres.
  • cardiac remodeling is meant to refer to a group of molecular, cellular and interstitial changes that manifest clinically as changes in size, mass, geometry and function of the heart after injury. Often, the process results in poor prognosis because of its association with ventricular dysfunction and malignant arrhythmias.
  • cardiomyopathy is meant to refer to any disease or condition involving injured cardiomyocytes.
  • cardiovascular disease encompasses diseases and disorders of the muscle and/or blood vessels of the heart, diseases and disorders of the vascular system, and/or diseases and disorders of organs and anatomical systems caused by the diseased condition of the heart and/or vasculature.
  • Examples include, but are not limited to: inflammation of the heart and/or vasculature such as myocarditis, chronic autoimmune myocarditis, bacterial and viral myocarditis, as well as infective endocarditis; heart failure; congestive heart failure; chronic heart failure; cachexia of heart failure; cardiomyopathy, including non-ischemic (dilated cardiomyopathy; idiopathic dilated cardiomyopathy; cardiogenic shock, heart failure secondary to extracorporeal circulatory support (“post-pump syndrome”), heart failure following ischemia/reperfusion injury, brain death associated heart failure (as described in Owen et al., 1999 (Circulation.
  • cardiomyopathy 1999 May 18; 99(19):2565-70
  • hypertrophic cardiomyopathy restrictive cardiomyopathy; non-ischemic systemic hypertension; valvular disease; arythmogenic right ventricular cardiomyopathy) and ischemic (atherogenesis; atherosclerosis; arteriosclerosis; peripheral vascular disease; coronary artery disease; infarctions, including stroke, transient ischemic attacks and myocardial infarctions).
  • myocardial injury is meant to encompass all conditions causing cardiomyocyte death.
  • conditions associated with myocardial injury are meant to include any disease or disorder comprising injury of myocardial cells.
  • conditions associated with myocardial injury are those in which cardiomyocytes are stressed or injured leading to inflammation and fibrosis, apoptosis and/or necrosis.
  • myocardial contusion is a type of myocardial injury and refers to a bruise of the heart muscle. Myocardial contusions may be completely silent or cause an arrhythmia (supraventricular tachycardia or ventricular fibrillation) or hypotension secondary to reduced cardiac output.
  • myocardial fibrosis is meant to refer to a significant increase in the collagen volume of myocardial tissue. It is a complex process that involves all components of the myocardial tissue and can be triggered by tissue injury from myocardial ischemia (hypoxia), inflammation, and hypertensive overload. To reverse replacement fibrosis, resorption of fibrous tissue needs to be coupled with robust myocardial regeneration. The latter is currently not feasible in adult human hearts. Reversal of interstitial fibrosis poses several challenges (see text) and may require co-operation of several different cell types.
  • congestive heart failure is meant to refer to a condition of myocardial injury that is characterized by impaired cardiac function that renders the heart unable to maintain the normal blood output at rest or with exercise, or to maintain a normal cardiac output in the setting of normal cardiac filling pressure.
  • a left ventricular ejection fraction of about 40% or less is indicative of congestive heart failure (by way of comparison, an ejection fraction of about 60% percent is normal).
  • Patients in congestive heart failure display well-known clinical symptoms and signs, such as tachypnea, pleural effusions, fatigue at rest or with exercise, contractile dysfunction, and edema.
  • Congestive heart failure is readily diagnosed by well known methods (see, e.g., “Consensus recommendations for the management of chronic heart failure.” Am. J. Cardiol., 83(2A):lA-38-A, 1999).
  • ischemic heart disease is meant to refer to any disorder resulting from an imbalance between the myocardial need for oxygen and the adequacy of the oxygen supply. Most cases of ischemic heart disease result from narrowing of the coronary arteries, as occurs in atherosclerosis or other vascular disorders.
  • myocardial ischemia refers to when blood flow to the heart muscle (myocardium) is obstructed by a partial or complete blockage of a coronary artery by a buildup of plaques (atherosclerosis).
  • MI myocardial infarction
  • cardiotoxic is meant a compound that decreases heart function by directing or indirectly impairing or killing cardiomyocytes.
  • hypotension is meant to refer to blood pressure that is considered by a medical professional (e.g., a physician or a nurse) to be higher than normal and to carry an increased risk for developing congestive heart failure.
  • an "effective amount" of a compound is meant to refer to a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, for example, an amount which results in the prevention of or a decrease in the symptoms associated with a disease that is being treated, e.g., myocardial injury.
  • the amount of compound administered to the subject will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
  • an effective amount of the compounds of the present disclosure sufficient for achieving a therapeutic or prophylactic effect, range from about 0.000001 mg per kilogram body weight per day, to about 10,000 mg per kilogram body weight per day.
  • the dosage ranges are from about 0.0001 mg per kilogram body weight per day to about 100 mg per kilogram body weight per day.
  • the compounds of the present disclosure can also be administered in combination with each other, or with one or more additional therapeutic compounds.
  • reducing or preventing apoptosis is meant preventing apoptosis or reducing the levels of apoptosis in a cardiomocyte as compared with an equivalent untreated control; such reduction or degree of prevention is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100% as measured by any standard technique.
  • Standard techniques include for example DNA laddering, TUNEL assay, flow cytometry for DNA content, cell death ELISA, caspase activity, or detection of surrogate markers of apoptosis by immunohistochemistry, Western or Northern analysis.
  • reducing or preventing pericarditis is meant preventing pericarditis or reducing the levels of pericarditis in a cardiomocyte as compared with an equivalent untreated control; such reduction or degree of prevention is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100% as measured by any standard technique.
  • treating, reducing, or preventing ischemic-reperfusion injury or by “treating, reducing or preventing a cardiac disorder” is meant treating, or ameliorating such injury or cardiac disorder, respectively, before or after it has occurred.
  • reduction or degree of prevention is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100% as measured by any standard technique known in the art.
  • ST elevation refers to the ST segment of an electrocardiogram where the myocardial cells have gone through depolarization, but not repolarization. This segment should be on the isoelectric line because the there should be no voltage difference across the cardiac muscle cell membrane at this point.
  • STMI refers to a ST elevation myocardial infarction
  • NSTEMI refers to a non-ST elevation myocardial infarction. NSTEMI is a type of heart attack that happens when the heart’s need for oxygen cannot be met.
  • iatrogenically-induced is meant a condition that is of longer duration than acute, and is planned, or is a consequence of a medical treatment (for example, open heart surgery or chemotherapy).
  • an “isolated” or “purified” polypeptide or polypeptide or biologically-active portion thereof is substantially free of cellular material or other contaminating polypeptides from the cell or tissue source from which the tissue differentiation factor-related polypeptide is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized.
  • polypeptide As used herein, the terms “polypeptide”, “peptide” and “protein” are used interchangeably herein to refer to a natural or synthetic peptide containing two or more amino acids linked typically via the carboxy group of one amino acid and the amino group of another amino acid. As will be appreciated by those having skill in the art, the above definition is not absolute and polypeptides or peptides can include other examples where one or more amide bonds could be replaced by other bonds, for example, isosteric amide bonds. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
  • polypeptide The essential nature of such analogues of naturally occurring amino acids is that, when incorporated into a protein, that protein is specifically reactive to antibodies elicited to the same protein but consisting entirely of naturally occurring amino acids.
  • polypeptide The terms “polypeptide”, “peptide” and “protein” also are inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gammacarboxylation of glutamic acid residues, hydroxylation, and ADP-ribosylation. It will be appreciated, as is well known and as noted above, that polypeptides may not be entirely linear.
  • polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslational events, including natural processing event and events brought about by human manipulation which do not occur naturally.
  • Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well.
  • the term “pharmaceutically acceptable carrier” includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions such as an oil/water or water/oil, and various types of wetting agents.
  • the term also encompasses any of the agents approved by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including humans, as well as any carrier or diluent that does not cause significant irritation to a subject and does not abrogate the biological activity and properties of the administered compound.
  • small molecule is meant to refer to a composition that has a molecular weight of less than about 5 kDa and more preferably less than about 2 kDa.
  • Small molecules can be, e.g., nucleic acids, peptides, polypeptides, glycopeptides, peptidomimetics, carbohydrates, lipids, lipopolysaccharides, combinations of these, or other organic or inorganic molecules.
  • the terms “subject,” “individual,” “host,” and “patient,” are used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans. The methods described herein are applicable to both human therapy and veterinary applications.
  • the subject is a mammal, and in other embodiments the subject is a human.
  • a “subject in need” is meant to refer to a subject that (i) will be administered a TDFRP.
  • the terms “therapeutic amount”, “therapeutically effective amount”, an “amount effective”, or “pharmaceutically effective amount” of an active agent e.g. a TDFRP), as described herein, are used interchangeably to refer to an amount that is sufficient to provide the intended benefit of treatment.
  • dosage levels are based on a variety of factors, including the type of injury, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular active agent employed. Thus the dosage regimen may vary widely, but can be determined routinely by a physician using standard methods.
  • the terms “therapeutic amount”, “therapeutically effective amounts” and “pharmaceutically effective amounts” include prophylactic or preventative amounts of the compositions of the disclosure.
  • compositions or medicaments are administered to a patient susceptible to, or otherwise at risk of, a disease, disorder or condition in an amount sufficient to eliminate or reduce the risk, lessen the severity, or delay the onset of the disease, disorder or condition, including biochemical, histologic and/or behavioral symptoms of the disease, disorder or condition, its complications, and intermediate pathological phenotypes presenting during development of the disease, disorder or condition. It is generally preferred that a maximum dose be used, that is, the highest safe dose according to some medical judgment.
  • dose and “dosage” are used interchangeably herein.
  • treating is meant that administration of a TDFRP slows or inhibits the progression of myocardial injury and/or conditions associated with myocardial injury during the treatment, relative to the disease progression that would occur in the absence of treatment, in a statistically significant manner.
  • Well known indicia such as left ventricular ejection fraction, exercise performance, and other clinical tests as enumerated above, as well as survival rates and hospitalization rates may be used to assess disease progression.
  • Whether or not a treatment slows or inhibits disease progression in a statistically significant manner may be determined by methods that are well known in the art (see, e.g., SOLVD Investigators, N. Engl. J. Med. 327:685-691, 1992 and Cohn et al., N. Engl. J. Med. 339:1810-1816, 1998).
  • preventing is meant minimizing or partially or completely inhibiting the development of myocardial injury and/or conditions associated with myocardial injury in a mammal at risk for developing congestive heart failure (as defined in “Consensus recommendations for the management of chronic heart failure.” Am. J. Cardiol., 83(2A):lA-38-A, 1999). Determination of whether myocardial injury and conditions associated with myocardial injury is minimized or prevented by administration of a TDFRP is made by known methods, such as those described in SOLVD Investigators, supra, and Cohn et al., supra.
  • being “at risk for myocardial injury” is meant to refer to an individual who smokes, is obese (i.e., 20% or more over their ideal weight), has been or will be exposed to a cardiotoxic compound (such as a chemotherapeutic or an anthracycline antibiotic), or has (or had) high blood pressure, ischemic heart disease, a myocardial infarct, a genetic defect known to increase the risk of heart failure, a family history of heart failure, myocardial hypertrophy, hypertrophic cardiomyopathy, left ventricular systolic dysfunction, coronary bypass surgery, vascular disease, atherosclerosis, alcoholism, periocarditis, a viral infection, gingivitis, or an eating disorder (e.g., anorexia nervosa or bulimia), or is an alcoholic or cocaine addict.
  • a cardiotoxic compound such as a chemotherapeutic or an anthracycline antibiotic
  • therapeutic effect refers to a consequence of treatment, the results of which are judged to be desirable and beneficial.
  • a therapeutic effect can include, directly or indirectly, the arrest, reduction, or elimination of a disease manifestation.
  • a therapeutic effect can also include, directly or indirectly, the arrest reduction or elimination of the progression of a disease manifestation.
  • the therapeutically effective amount may be initially determined from preliminary in vitro studies and/or animal models.
  • a therapeutically effective dose may also be determined from human data.
  • the applied dose may be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other well-known methods is within the capabilities of the ordinarily skilled artisan.
  • General principles for determining therapeutic effectiveness which may be found in Chapter 1 of Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill (New York) (2001), incorporated herein by reference, are summarized below.
  • Pharmacokinetic principles provide a basis for modifying a dosage regimen to obtain a desired degree of therapeutic efficacy with a minimum of unacceptable adverse effects. In situations where the drug's plasma concentration can be measured and related to the therapeutic window, additional guidance for dosage modification can be obtained.
  • Drug products are considered to be pharmaceutical equivalents if they contain the same active ingredients and are identical in strength or concentration, dosage form, and route of administration. Two pharmaceutically equivalent drug products are considered to be bioequivalent when the rates and extents of bioavailability of the active ingredient in the two products are not significantly different under suitable test conditions.
  • variant is meant to refer to a compound that differs from the compound of the present disclosure but retains essential properties thereof.
  • a non-limiting example of this is a polynucleotide or polypeptide compound having conservative substitutions with respect to the reference compound, commonly known as degenerate variants.
  • Another non-limiting example of a variant is a compound that is structurally different but retains the same active domain of the compounds of the present disclosure.
  • Variants include N-terminal or C-terminal extensions, capped amino acids, modifications of reactive amino acid side chain functional groups, e.g., branching from lysine residues, pegylation, and/or truncations of a polypeptide compound.
  • variants are overall closely similar, and in many regions, identical to the compounds of the present disclosure. Accordingly, the variants may contain alterations in the coding regions, non-coding regions, or both.
  • compositions comprising at least one TDFRP.
  • TDFRPs Tissue Differentiation Factor Related Polypeptides
  • the present disclosure provides compounds that are functional analogs of tissue differentiation factors, i.e., compounds that functionally mimic TGF-beta superfamily proteins, for example by acting as TGF-beta superfamily receptor agonists, and preferentially bind to select ALK receptor(s).
  • the present compounds are called TDFRPs, and include small molecules, more particularly polypeptides.
  • the TDFRP compound has the general structure identified as SEQ ID NOs: 1-208, disclosed in International Publication No. WG/2003/106656, incorporated by reference in its entirety herein.
  • a TDFRP compound includes an analog or homolog of SEQ ID NOs: 1-208.
  • Compounds of the present disclosure include those with homology to SEQ ID Nos: 1-208, for example, preferably 50% or greater amino acid identity, more preferably 75% or greater amino acid identity, and even more preferably 90% or greater amino acid identity.
  • the compounds of the present disclosure also include one or more polynucleotides encoding SEQ ID Nos: 1-208, including degenerate variants thereof. Accordingly, nucleic acid sequences capable of hybridizing at low stringency with any nucleic acid sequences encoding SEQ ID Nos:l- 208 are considered to be within the scope of the disclosure.
  • the TDFRP compound has the general structure identified as SEQ ID NOs: 1-347, disclosed in International Publication No. WO/2007/035872, incorporated by reference in its entirety herein.
  • a TDFRP compound includes an analog or homolog of SEQ ID NOs: 1-347.
  • Compounds of the present disclosure include those with homology to SEQ ID Nos: 1-347, for example, preferably 50% or greater amino acid identity, more preferably 75% or greater amino acid identity, and even more preferably 90% or greater amino acid identity.
  • the compounds of the present disclosure also include one or more polynucleotides encoding SEQ ID Nos: 1-347, including degenerate variants thereof. Accordingly, nucleic acid sequences capable of hybridizing at low stringency with any nucleic acid sequences encoding SEQ ID Nos:l- 347 are considered to be within the scope of the disclosure.
  • the TDFRP compound has the general structure identified as SEQ ID NOs: 1-314, disclosed in International Publication No. WO/2006/009836, incorporated by reference in its entirety herein.
  • a TDFRP compound includes an analog or homolog of SEQ ID NOs:l-314.
  • Compounds of the present disclosure include those with homology to SEQ ID Nos: 1-314, for example, preferably 50% or greater amino acid identity, more preferably 75% or greater amino acid identity, and even more preferably 90% or greater amino acid identity.
  • the compounds of the present disclosure also include one or more polynucleotides encoding SEQ ID Nos: 1-314, including degenerate variants thereof.
  • the TDFRP compound has the general structure set forth as SEQ ID NOs:l-77, disclosed in International Publication No. WO/2013/013085 incorporated by reference in its entirety herein.
  • a TDFRP compound includes an analog or homolog of SEQ ID NOs:l-77.
  • Compounds of the present disclosure include those with homology to SEQ ID Nos: 1-77, for example, preferably 50% or greater amino acid identity, more preferably 75% or greater amino acid identity, and even more preferably 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino acid identity.
  • the compounds of the present disclosure also include one or more polynucleotides encoding one or more of SEQ ID Nos: 1-77, including degenerate variants thereof. Accordingly, nucleic acid sequences capable of hybridizing at low stringency with any nucleic acid sequences encoding SEQ ID Nos: 1-77 are considered to be within the scope of the disclosure.
  • Sequence identity can be measured using sequence analysis software (Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705), with the default parameters therein.
  • non-identical positions are preferably, but not necessarily, conservative substitutions for the reference sequence.
  • Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine.
  • conservative interchanges include those within the aliphatic group aspartate and glutamate; within the amide group asparagine and glutamine; within the hydroxyl group serine and threonine; within the aromatic group phenylalanine, tyrosine, and tryptophan; within the basic group lysine, arginine, and histidine; and within the sulfur-containing group methionine and cysteine. Sometimes substitution within the group methionine and leucine can also be considered conservative.
  • the peptide is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9% identical to SEQ ID NO: 16. According to some embodiments of the embodiments and aspects herein, the peptide is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9% identical to SEQ ID NO: 17. According to some embodiments of the embodiments and aspects herein, the peptide is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9% identical to SEQ ID NO: 18. According to some embodiments of the embodiments and aspects herein, the peptide consists of SEQ ID NO: 10.
  • the peptide consists of SEQ ID NO: 17. According to some embodiments of the embodiments and aspects herein, the peptide consists of SEQ ID NO: 18.
  • SEQ ID NOs 10-18 set forth above further comprise a N- terminal (H) and a C-terminal (OH):
  • the peptide is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9% identical to SEQ ID NO: 4. According to some embodiments of the embodiments and aspects herein, the peptide is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9% identical to SEQ ID NO: 5. According to some embodiments of the embodiments and aspects herein, the peptide is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9% identical to SEQ ID NO: 6.
  • the peptide is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9% identical to SEQ ID NO: 7. According to some embodiments of the embodiments and aspects herein, the peptide is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9% identical to SEQ ID NO: 8. According to some embodiments of the embodiments and aspects herein, the peptide is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 9% identical to SEQ ID NO: 9. According to some embodiments of the embodiments and aspects herein, the peptide consists of SEQ ID NO: 1.
  • the peptide consists of SEQ ID NO: 2. According to some embodiments of the embodiments and aspects herein, the peptide consists of SEQ ID NO: 3. According to some embodiments of the embodiments and aspects herein, the peptide consists of SEQ ID NO: 4. According to some embodiments of the embodiments and aspects herein, the peptide consists of SEQ ID NO: 5. According to some embodiments of the embodiments and aspects herein, the peptide consists of SEQ ID NO: 6. According to some embodiments of the embodiments and aspects herein, the peptide consists of SEQ ID NO: 7.
  • the peptide consists of SEQ ID NO: 8. According to some embodiments of the embodiments and aspects herein, the peptide consists of SEQ ID NO: 9.
  • the disclosure includes vectors containing one or more nucleic acid sequences encoding a TDFRP compound.
  • the nucleic acid containing all or a portion of the nucleotide sequence encoding the polypeptide is inserted into an appropriate cloning vector, or an expression vector (i.e., a vector that contains the necessary elements for the transcription and translation of the inserted polypeptide coding sequence) by recombinant DNA techniques well known in the art and as detailed below.
  • regulatory sequence is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences).
  • GST glutathione S-transferase
  • suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET l id (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).
  • the disclosure further provides a recombinant expression vector comprising a DNA molecule of the disclosure cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to a TDRFP mRNA.
  • Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA.
  • the antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
  • a high efficiency regulatory region the activity of which can be determined by the cell type into which the vector is introduced.
  • a host cell can be any prokaryotic or eukaryotic cell.
  • TDFRP can be expressed in bacterial cells such as E. coll, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.
  • Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
  • transformation and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride coprecipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2 nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.
  • a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
  • selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate.
  • Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding TDFRP or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
  • a host cell that includes a compound of the disclosure can be used to produce (i.e., express) recombinant TDFRP.
  • the method comprises culturing the host cell of disclosure (into which a recombinant expression vector encoding TDFRP has been introduced) in a suitable medium such that TDFRP is produced.
  • the method further comprises the step of isolating TDFRP from the medium or the host cell. Purification of recombinant polypeptides is well-known in the art and include ion-exchange purification techniques, or affinity purification techniques, for example with an antibody to the compound.
  • a TDFRP-derived “chimeric polypeptide” or “fusion polypeptide” comprises a TDFRP operatively-linked to a polypeptide having an amino acid sequence corresponding to a polypeptide that is not substantially homologous to the TDFRP, e.g., a polypeptide that is different from the TDFRP and that is derived from the same or a different organism (i.e., non- TDFRP).
  • the TDFRP can correspond to all or a portion of a TDFRP.
  • inert groups which can serve as linking groups include aliphatic chains such as alkyl, alkenyl and alkynyl groups (e.g., C1-C20), cycloalkyl rings e.g., C3-C10), aryl groups (carbocyclic aryl groups such as 1- naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl and heteroaryl group such as /V-imidazolyl, 2- imidazole, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidy, 4- pyrimidyl, 2-pyranyl, 3-pyranyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-pyrazinyl, 2-thiazole, 4- thiazole, 5-thiazole, 2-oxazolyl, 4-oxazolyl,
  • TGF-b/BMPs Superfamily members are associated with a number of cellular activities involved in injury responses and regeneration.
  • TDFRP compounds can be used as agonists of BMPs or antagonists of TGF-b molecules to mediate activities that can prevent, repair or alleviate injurious responses in cells, tissues or organs. Key activities involved in mediating these effects would be antiinflammatory, anti-apoptotic and anti-fibrotic properties.
  • Several in vitro models for inflammation can be used to assess cytokine, chemokine and cell adhesion responses, which are well-documented markers of inflammation.
  • TNF-a tumor necrosis factor-alpha
  • LPS lipopolysaccharide
  • pro-inflammatory molecules for example, IL-1, IL-6, IL-8, NF-kappaB
  • adhesion molecules for example, intercellular adhesion molecule-1 or ICAM-1.
  • these agents induce chemokines (IL-6, IL-8, monocyte chemoattractant protein- 1 or MCP-1 and RANTES), which cause immune cells to infiltrate tissues resulting in organ damage.
  • chemokines IL-6, IL-8, monocyte chemoattractant protein- 1 or MCP-1 and RANTES
  • Apoptosis or programmed cell death is initiated through either a mitochondrial pathway, in response to stress factors or through a receptor-mediated pathway, triggered by the binding of ligands, such as TNF-a.
  • ligands such as TNF-a.
  • Multiple factors contribute to the complex apoptotic process, including the infiltration neutrophils and other inflammatory cells that activate a class of enzymes known as caspases.
  • Other useful markers of apoptosis are Bax and the human vascular anticoagulant, Annexin V, which binds to a protein that gets translocated from the inner to the outer plasma membrane in apoptotic cells.
  • the anti-apoptotic activity of TDFRP compounds can be assessed using in vitro models of apoptosis in cultured cells (for example, heart muscle cells or cardiomyocytes) .
  • cultured cells for example, heart muscle cells or cardiomyocytes
  • Cardiomyocytes rarely proliferate in adult cardiac muscles and the loss of cardiac muscle cells can lead to permanent loss of cardiac function.
  • Myocardial apoptosis caused by injury to cardiomyoctes, contributes to or aggravates the development of myocardial dysfunction in various cardiac diseases.
  • the chemotherapeutic agent, doxorubicin causes heart failure, a reduced number of functioning cardiac muscle cells, activation of caspase 3 and apoptosis.
  • the anti-apoptotic activity of TDFRP compounds can be demonstrated by showing the inhibition of Bax and caspase-3 expression that was induced by doxorubicin, LPS or ischemia, as well as by showing an increase in the levels of phosphorylated Akt, a sensitive indicator of cardiomyocyte health.
  • MI Myocardial injury
  • MI Myocardial ischemia
  • TPA administered soon after a myocardial infarction, limits damage (by reopening the blood vessel) but has no effect on the cellular processes of apoptosis, inflammation, and fibrosis.
  • TDFRP compounds can be used to demonstrate anti-inflammatory and anti-apoptotic activities in cultured cardiomyoctes.
  • TDFRP compounds can be used to reduce the size of infarct, maintain coronary artery endothelial function and inhibit neutrophil adherence to vascular endothelium (reduced reperfusion injury) in rat models of MI.
  • the MI rat model (called the Left Anterior Descending Artery (LAD) occlusion model) involves the transient ligation of the left anterior descending artery to create ischemia.
  • LAD Left Anterior Descending Artery
  • TDFRP compounds can be administered before and after ischemia induced by ligation of the heart ventricle. Efficacy can be determined by morphology and by assessing Creatine Kinase - Myocardioband (CK- MB) levels between infarct and non-infarct regions of the ventricle following reperfusion.
  • CK- MB Creatine Kinase - Myocardioband
  • TDFRPs to block and reverse the intracellular pathways in cardiomyocytes that lead to inflammation and apoptosis, thereby preventing necrosis and fibrosis.
  • the disclosure features a method of treating a condition that is associated with myocardial injury, the method comprising administering to a subject in need of treatment at least one tissue differentiation factor related polypeptide (TDFRP).
  • TDFRP tissue differentiation factor related polypeptide
  • the disclosure features a method of preventing a condition that is associated with myocardial injury, the method comprising administering to a subject in need of prevention at least one TDFRP.
  • cardiomyocytes can be injured. Some of those injuries are immediate, and include, but are not limited to: ischemia, myocardial infarction, chronic arterial insufficiency, atherosclerosis, mechanical stress (e.g., over work of cardiomyocytes), pressure overload, due to valvular obstruction, hypertension, volume overload and arrhythmias.
  • Autoimmune diseases can also lead to myocardial injury, and include, but are not limited to, Systemic Lupus Erythematosis and Scleroderma.
  • TDFRPs represent a possible chronic treatment or preventative treatment for myocardial injury associated with the autoimmune diseases.
  • DCM Dilated Cardiomyopathy
  • treatment may include medications in the ACE inhibitor, beta blocker, and diuretic families.
  • a low salt diet may also be helpful.
  • blood thinners or an implantable cardioverter defibrillator may be recommended.
  • Cardiac resynchronization therapy (CRT) may be necessary. If other measures are not effective a heart transplant may be an option in some.
  • Takotsubo cardiomyopathy or Takotsubo syndrome also known as stress cardiomyopathy, is a type of non-ischemic cardiomyopathy in which there is a sudden temporary weakening of the muscular portion of the heart. It usually appears after a significant stressor, either physical or emotional; when caused by the latter, the condition is sometimes called broken heart syndrome. Examples of physical stressors that can cause TTS are sepsis, shock, and pheochromocytoma, and emotional stressors include bereavement, divorce, or the loss of a job. Reviews suggest that of patients diagnosed with the condition, about 70-80% recently experienced a major stressor, including 41-50% with a physical stressor and 26-30% with an emotional stressor. TTS can also appear in patients who have not experienced major stressors.
  • ICM Coronary infarct
  • Ischemic cardiomyopathy is a type of cardiomyopathy caused by a narrowing of the coronary arteries which supply blood to the heart.
  • patients with ischemic cardiomyopathy have a history of acute myocardial infarction, however, it may occur in patients with coronary artery disease, but without a past history of acute myocardial infarction.
  • This cardiomyopathy is one of the leading causes of sudden cardiac death.
  • the adjective ischemic means characteristic of, or accompanied by, ischemia — local anemia due to mechanical obstruction of the blood supply.
  • therapeutic uses include, but are no limited to, untreatable chronic conditions that result in cardiomyopathy.
  • untreatment conditions include, but are not limited to, such as autoimmune disease, pulmonary insufficiency, haemochromatosis, Anderson-Fabry disease, glycogen storage disease, medications for treating chronic conditions for which a side effect is cardiomyopathy, Gaucher’s disease, Hurler’s disease, Hunter’s disease, diabetes mellitus, hyper and hypothyroidism, hyperparathyroidism, and pheochromocytoma.
  • the disclosure features a method of preventing a condition that is associated with myocardial injury, the method comprising administering to a subject in need of treatment at least one tissue differentiation factor related polypeptide (TDFRP).
  • TDFRP tissue differentiation factor related polypeptide
  • TDFPRs are used prophylactically, for example to prevent damage from a planned event such as the use of doxorubicin for chemotherapy or prior to a major operative procedure where either a long period under anesthesia is anticipated and/or open-heart surgery where a cardio-pulmonary pump may or will be used.
  • a planned event such as the use of doxorubicin for chemotherapy or prior to a major operative procedure where either a long period under anesthesia is anticipated and/or open-heart surgery where a cardio-pulmonary pump may or will be used.
  • Isolated cardiomyocyte cultures or cardiomyocytes present within cardiac tissue or the heart organ may be treated with the TDFRPs described herein.
  • a cardiomyocyte according to the methods of the present disclosure may be derived from any mammal, including for example, a pig, mouse, or non-human primate monkey. Cardiomyocytes amenable to treatment may be of any maturity state, and thus include neonatal cardiomyocytes, stem cells, cells committed to differentiate to cardiomyocytes, a myocyte derived from a non-heart muscle, a myoblast, or adult cardiomyocytes.
  • a more complex in vitro system that better mimics the in vivo setting may be used for testing the efficacy of a compound or analog, e.g., TDFRP compound
  • Flow cytometry may also be used to measure DNA content in cardiomyocytes.
  • Cells are fixed with 80% ethanol and stained with propidium iodide after RNase treatment. Apoptotic cells register as containing less than the diploid DNA quantity (2N).
  • TUNEL staining can be performed using Apoptag (Intergen) according to the manufacturer's instructions, with Hoechst 33258 (Sigma) nuclear counter-staining.
  • DNA laddering can also be used to detect apoptosis of cardiomyocytes.
  • Fresh tissues (without TTC staining) are microdissected under UV light into ischemic and non-ischemic regions and processed simultaneously. Tissues from each region are lysed and DNA is prepared, labeled with [a-32P] dCTP, and subjected to electrophoresis and autoradiography as described by Vazquez- Jimenez et al (J. Am. Coll. Cardiol., 2001).
  • apoptosis of cardiomyocytes may further be determined by the detection of surrogate markers of apoptosis, such caspase activation, for example.
  • compositions of the disclosure typically contain a therapeutically effective amount of a compound described herein.
  • a pharmaceutical composition may contain more than a therapeutically effective amount, such as in bulk compositions, or less than a therapeutically effective amount, that is, individual unit doses designed for multiple administration to achieve a therapeutically effective amount.
  • the composition will contain from about 0.01-95 wt % of active agent, including, from about 0.01-30 wt %, such as from about 0.01-10 wt %, with the actual amount depending upon the formulation itself, the route of administration, the frequency of dosing, and so forth.
  • a composition suitable for an oral dosage form may contain about 5-70 wt %, or from about 10-60 wt % of active agent.
  • Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols. Any of the above formulations may be a sustained-release formulation.
  • the polypeptide may be administered by administering an expression vector encoding the polypeptide to the mammal.
  • the promoter may be an inducible promoter, such as the ischemia-inducible promoter described in Prentice et al. (Cardiovasc. Res. 35:567-574, 1997).
  • Cell Applications Primary neonatal rat cardiomyocytes (Cell Applications) were cultured in medium with 10% growth supplement (Cell Applications) for 24 hours at 37° C., 5% CO2. Cells were then starved of growth supplement for 12 hours to create ischemic injury. Controls received medium alone. Cells were incubated with culture medium alone, BMP- 7 (143 nM) or SEQ ID No. 1 (100 pM) for 60 h.
  • BMP- 7 143 nM
  • SEQ ID No. 1 100 pM
  • Neonatal rat cardiomyocytes were pre -treated with 0.33 pM doxorubicin for 24h, followed by treatment with BMP-7 (143 nM) or SEQ ID No. 1 at 100 and 500 pM for 60h. Both BMP-7 and THR-123 (SEQ ID NO: 1) significantly inhibited doxorubicin induced Caspase-3 activity (p ⁇ 0.05) (FIG. 3). Caspase-3 activation is a step common to both apoptotic pathways and leads to apoptosis.
  • Example 4 The effect of TDFRP peptide SEQ ID NO: 1 on LPS induced Caspase-3
  • TDFRP peptide SEQ ID NO: 1 reduces inflammation in cardiomyocytes
  • the animals were divided into three groups that were dosed with PBS, BMP-7, or THR-123 (SEQ ID NO: 1). Administrations were at 2 hr prior to ligation and at 24, 72 and 120 hr post ligation. On the seventh day post ligation the suture was tightened again and Methyl Blue was injected into the blood stream to stain region of the heart that the ligation did not affect (the unaffected region).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de manière générale des méthodes de traitement ou de prévention d'une lésion myocardique, ou d'un état pathologique associé à une lésion myocardique, chez un mammifère, la méthode comprenant l'administration d'au moins un polypeptide associé au facteur de différenciation tissulaire (TDFRP) au mammifère, et l'administration étant effectuée en une quantité efficace pour traiter ou prévenir une lésion myocardique chez ledit mammifère.
EP23801981.4A 2022-10-10 2023-10-10 Polypeptides associés au facteur de différenciation tissulaire (tdfrp) pour le traitement d'une lésion myocardique Pending EP4601667A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263414747P 2022-10-10 2022-10-10
PCT/US2023/034834 WO2024081245A1 (fr) 2022-10-10 2023-10-10 Polypeptides associés au facteur de différenciation tissulaire (tdfrp) pour le traitement d'une lésion myocardique

Publications (1)

Publication Number Publication Date
EP4601667A1 true EP4601667A1 (fr) 2025-08-20

Family

ID=88731281

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23801981.4A Pending EP4601667A1 (fr) 2022-10-10 2023-10-10 Polypeptides associés au facteur de différenciation tissulaire (tdfrp) pour le traitement d'une lésion myocardique

Country Status (2)

Country Link
EP (1) EP4601667A1 (fr)
WO (1) WO2024081245A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
ES2397327T3 (es) 2002-06-17 2013-03-06 Thrasos, Inc. Compuestos asociados a un dominio único de TDF y análogos de los mismos
AU2005265098B2 (en) 2004-06-17 2012-02-23 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
HUE026634T2 (en) 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
CA2842330A1 (fr) 2011-07-19 2013-01-24 Thrasos Innovation, Inc. Peptides anti-fibrotiques et leur utilisation dans des procedes de traitement de maladies et de troubles caracterises par la fibrose
EP4595974A3 (fr) * 2018-10-22 2025-08-13 William D. Carlson Combinaisons thérapeutiques de tdfrps et d'agents supplémentaires et procédés d'utilisation

Also Published As

Publication number Publication date
WO2024081245A1 (fr) 2024-04-18

Similar Documents

Publication Publication Date Title
US7045133B2 (en) VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
EP3510044B1 (fr) Analogues de l'amyline
AU2012240102B2 (en) Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
AU2019366366B2 (en) Therapeutic combinations of TDFRPs and additional agents and methods of use
US9938320B2 (en) Peptides for promoting angiogenesis and use thereof
KR20070017366A (ko) 관절염증 치료제 또는 예방제
CN102470156A (zh) 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途
AU2007218297B2 (en) Combination of Somatostatin-analogs with different selectivity for human Somatostatin receptor subtypes
EP2098244A1 (fr) Composition pharmaceutique pour le traitement de l'infarctus du myocarde
US20080153753A1 (en) Method of treating side effects induced by therapeutic agents
WO2024081245A1 (fr) Polypeptides associés au facteur de différenciation tissulaire (tdfrp) pour le traitement d'une lésion myocardique
WO2020085467A1 (fr) Composition pharmaceutique destinée au traitement de l'anémie aplasique
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
WO2003080103A1 (fr) Antagonistes de megaline ou de cubiline destines a etre utilises dans la prevention de l'endommagement d'organes induit par des agents therapeutiques
WO2024189056A1 (fr) Régime d'administration d'annexine a1
CN109310737B (zh) 治疗代谢疾病的组合物和方法
WO2021128919A1 (fr) Application de cst1 dans la prévention et/ou le traitement de maladies de dysfonctionnement immunitaire du foie
US20240123033A1 (en) THERAPEUTIC COMBINATIONS OF TDFRPs AND ADDITIONAL AGENTS AND METHODS OF USE FOR THE REVERSAL OF FIBROSIS
WO2022197842A1 (fr) Procédés de traitement de la fibrose pulmonaire associée à une infection virale à l'aide de polypeptides apparentés au facteur de différenciation tissulaire (tdfrps)
US20240342216A1 (en) Methods of treating cancer
CN112979764B (zh) 特异结合人cd47分子的多肽及其用途
KR102900540B1 (ko) 디프테리아 독소-인간 인터루킨-3 접합체를 다른 제제와 조합하여 사용해서 골수증식성 신생물을 치료하는 조합 치료 방법
EP2385840A1 (fr) Matériaux et méthodes pour le traitement de l' hypertension
EP1911459A1 (fr) Promoteur de lymphangiogenèse
US7326679B2 (en) Anticancer peptide compositions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR